Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

Blood (2024) 144 (Supplement 1): 217.

https://doi.org/10.1182/blood-2024-199882

Published: 2024

Journal Articles

High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Chong Chyn Chua, Natasha S Anstee, Anoop Kumar Enjeti, Devendra Hiwase, Paula Marlton, Ashish Bajel, Shuh Ying Tan, Edward S. Morris, Chun-Kei-Kris Ma, Carolyn Grove, Julian Cooney, Ashanka Beligaswatte, Rachel M Koldej, Stephen B Ting, Travis Perera, Amanda Johnston, John Reynolds, David Ritchie, Andrew H Wei

Blood (2022) 140 (Supplement 1): 3362–3364.

https://doi.org/10.1182/blood-2022-163084

Published: 2022

Journal Articles

Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

Rose Turner, Hang Quach, Noemi Horvath, Ian H Kerridge, Flora Yuen, Edwin Sze-Hung Lee, Edward S. Morris, Anna Kalff, Krystal Bergin, Shreerang Sridesai, Malgorzata Gorniak, Sridurga Mithraprabhu, Tiffany Khong, John Reynolds, Andrew Spencer

Blood (2021) 138 (Supplement 1): 1663.

https://doi.org/10.1182/blood-2021-152034

Published: 2021

Journal Articles

An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia

Chong Chyn Chua, John Reynolds, Anoop Kumar Enjeti, Devendra Hiwase, Paula Marlton, Ashish Bajel, Shuh Ying Tan, Edward S. Morris, Chun-Kei-Kris Ma, Carolyn Grove, Julian Cooney, Ashanka Beligaswatte, Natasha Anstee, Stephen B Ting, Travis Perera, Amanda Johnston, David Ritchie, Andrew H. Wei

Blood (2021) 138 (Supplement 1): 368.

https://doi.org/10.1182/blood-2021-149488

Published: 2021

Journal Articles

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Andrew Spencer, MBBS, FRACP, FRCPA, DM, Hang Quach, MD FRACP, FRCPA, MBBS, Noemi Horvath, MBBS FRACP FRCPA, Ian H. Kerridge, FRACP, FRCPA, MPhil, BA, Flora Yuen, BBiomedSc, Edwin Sze-Hung Lee, MD FRACP, FRCP, FRCPA, FRCPath, Edward S. Morris, BMBS, DM, Anna Kalff, MBBS, Krystal Bergin, Shreerang Sirdesai, MBBS, FRACP, FRCPA, Malgorzata Gorniak, BSc, Sridurga Mithraprabhu, PhD MSc, Tiffany Khong, BSc, PhD, John Reynolds, PhD

Blood (2018) 132 (Supplement 1): 3279.

https://doi.org/10.1182/blood-2018-99-113982

Published: 2018

Journal Articles

Soluble lymphotoxin is an important effector molecule in GVHD and GVL

Kate A. Markey, Angela C. Burman, Tatjana Banovic, Rachel D. Kuns, Neil C. Raffelt, Vanessa Rowe, Stuart D. Olver, Alistair L. J. Don, Edward S. Morris, Allison R. Pettit, Yana A. Wilson, Renee J. Robb, Louise M. Randall, Heinrich Korner, Christian R. Engwerda, Andrew D. Clouston, Kelli P. A. MacDonald, Geoffrey R. Hill

Blood (2010) 115 (1): 122–132.

https://doi.org/10.1182/blood-2009-01-199927

Published: 2010

Journal Articles

Invariant natural killer T cell–natural killer cell interactions dictate transplantation outcome after α-galactosylceramide administration

Rachel D. Kuns, Edward S. Morris, Kelli P. A. MacDonald, Kate A. Markey, Helen M. Morris, Neil C. Raffelt, Tatjana Banovic, Alistair L. J. Don, Vanessa Rowe, Angela C. Burman, Andrew D. Clouston, Camile Farah, Gurdyal S. Besra, Petr A. Illarionov, Mark J. Smyth, Steven A. Porcelli, Geoffrey R. Hill

Blood (2009) 113 (23): 5999–6010.

https://doi.org/10.1182/blood-2008-10-183335

Published: 2009

Journal Articles

Induction of Invariant NKT Cell-Dependent Alloreactivity by Administration of G-CSF after Bone Marrow Transplantation

Edward S Morris, DM, Kelli P A MacDonald, PhD, Rachel D Kuns, BSc, Helen M Morris, BSc, Tatjana Banovic, MD, Alistair LJ Don, BSc, Vanessa Rowe, MSc, Angela C Burman, PhD, Kate A Markey, BSc, Dale I Godfrey, PhD, Mark J Smyth, PhD, Geoff Hill, MD

Blood (2008) 112 (11): 3499.

https://doi.org/10.1182/blood.V112.11.3499.3499

Published: 2008

Journal Articles

Soluble Lymphotoxin Plays a Critical Role in Acute Graft-Versus-Host Disease

Kate A Markey, BE, Angela C Burman, PhD, Rachel D Kuns, BSc, Edward S Morris, MD, Tatjana Banovic, MD, Neil C Raffelt, BSc, Stuart D Olver, BSc, Christian R Engwerda, PhD, Heinrich Korner, PhD, Kelli P A MacDonald, PhD, Geoff R Hill, MD

Blood (2008) 112 (11): 3510.

https://doi.org/10.1182/blood.V112.11.3510.3510

Published: 2008

Journal Articles

IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract

Angela C. Burman, Tatjana Banovic, Rachel D. Kuns, Andrew D. Clouston, Amanda C. Stanley, Edward S. Morris, Vanessa Rowe, Helen Bofinger, Renae Skoczylas, Neil Raffelt, Olivier Fahy, Shaun R. McColl, Christian R. Engwerda, Kelli P. A. McDonald, Geoffrey R. Hill

Blood (2007) 110 (3): 1064–1072.

https://doi.org/10.1182/blood-2006-12-063982

Published: 2007

Includes: Supplemental data

Journal Articles

Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD

Kelli P. A. MacDonald, Rachel D. Kuns, Vanessa Rowe, Edward S. Morris, Tatjana Banovic, Helen Bofinger, Brendan O'Sullivan, Kate A. Markey, Alistair L. Don, Ranjeny Thomas, Geoffrey R. Hill

Blood (2007) 109 (11): 5049–5057.

https://doi.org/10.1182/blood-2007-01-067249

Published: 2007

Includes: Supplemental data

Journal Articles

Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation

Vanessa Rowe, Tatjana Banovic, Kelli P. MacDonald, Rachel Kuns, Alistair L. Don, Edward S. Morris, Angela C. Burman, Helen M. Bofinger, Andrew D. Clouston, Geoffrey R. Hill

Blood (2006) 108 (7): 2485–2492.

https://doi.org/10.1182/blood-2006-04-016063

Published: 2006

Journal Articles

Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?

Edward S. Morris, Kelli P. A. MacDonald, Geoffrey R. Hill

Blood (2006) 107 (9): 3430–3435.

https://doi.org/10.1182/blood-2005-10-4299

Published: 2006

Journal Articles

Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated-G-CSF.

Geoff Hill, MD, Edward S. Morris, MD, Maddona Fuery, Cheryl Hutchins, PhD, Jason Butler, MD, Andrew Grigg, MD, Andrew Roberts, MD, Ken Bradstock, MD, Jeffrey Szer, MD, Glen Kennedy, MD, James Morton, MD, Simon Durrant, MD

Blood (2005) 106 (11): 1970.

https://doi.org/10.1182/blood.V106.11.1970.1970

Published: 2005

Journal Articles

TGF-β in allogeneic stem cell transplantation: friend or foe?

Tatjana Banovic, Kelli P. A. MacDonald, Edward S. Morris, Vanessa Rowe, Rachel Kuns, Alistair Don, Jane Kelly, Steve Ledbetter, Andrew D. Clouston, Geoffrey R. Hill

Blood (2005) 106 (6): 2206–2214.

https://doi.org/10.1182/blood-2005-01-0062

Published: 2005

Journal Articles

Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance

Edward S. Morris, Kelli P. A. MacDonald, Vanessa Rowe, Diana H. Johnson, Tatjana Banovic, Andrew D. Clouston, Geoffrey R. Hill

Blood (2004) 103 (9): 3573–3581.

https://doi.org/10.1182/blood-2003-08-2864

Published: 2004

NARROW

A Phase II Randomized Trial Comparing Low-Dose Cytarabine and Venetoclax +/- Midostaurin in Non-Adverse Cytogenetic Risk Acute Myeloid Leukemia: The ALLG AMLM25 Intervene Trial

High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study

Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy - Final Analysis from the Australasian Leukemia and Lymphoma Group (ALLG) MM17 Trial

An Australasian Leukemia Lymphoma Group (ALLG) Phase 2 Study to Investigate Novel Triplets to Extend Remission with Venetoclax in Elderly (INTERVENE) Acute Myeloid Leukemia

Preliminary Analysis of the Australasian Leukaemia and Lymphoma Group (ALLG) MM17 Trial: Response Adaptive Salvage Treatment with Carfilzomib-Thalidomide-Dexamethasone (KTd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Soluble lymphotoxin is an important effector molecule in GVHD and GVL

Invariant natural killer T cell–natural killer cell interactions dictate transplantation outcome after α-galactosylceramide administration

Induction of Invariant NKT Cell-Dependent Alloreactivity by Administration of G-CSF after Bone Marrow Transplantation

Soluble Lymphotoxin Plays a Critical Role in Acute Graft-Versus-Host Disease

IFNγ differentially controls the development of idiopathic pneumonia syndrome and GVHD of the gastrointestinal tract

Effector and regulatory T-cell function is differentially regulated by RelB within antigen-presenting cells during GVHD

Host B cells produce IL-10 following TBI and attenuate acute GVHD after allogeneic bone marrow transplantation

Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL?

Allogeneic Stem Cell Transplantation with Peripheral Blood Stem Cells Mobilized by Pegylated-G-CSF.

TGF-β in allogeneic stem cell transplantation: friend or foe?

Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only